Trial NCT06018116

View at ClinicalTrials.gov 
Org. Study IDs: MP-20-2024-6963

Last trial update was posted on 2024-02-15

MeSH Interventions

Antibodies, Monoclonal Avelumab Bicalutamide

MeSH Conditions

Carcinoma, Transitional Cell

Other Conditions

Metastatic Urothelial Carcinoma

Stopping Reasons

Results of EV302 study do not make it feasible to complete a study in second line avelumab immunotherapy. The new standard of care make this study not pertinent.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID